S100P (S100 calcium binding protein P)

Our findings provide novel diagnostic and prognostic biomarker candidates and insights into mechanisms driving EOC progression with histotype- and stage-specificity. This may aid the development of improved clinical tools for detection, patient stratification, and targeted therapies in EOC.

Functionally, IL-27 blockade accelerated tumor growth, whereas recombinant IL-27 restrained tumor progression and enhanced PD-L1/CTLA-4 blockade efficacy by augmenting Th1 and cytotoxic T cell responses. These findings define a TME-based prognostic classifier and position IL-27 as a stage-dependent therapeutic target that restores T cell immunity and boosts checkpoint blockade efficacy.

This study demonstrated the utility of the S100P in DF analysis for the early diagnosis of PDAC and clarified potential issues related to sample collections in the actual clinical settings.

An immunohistochemical immunohistochemical panel including MTAP and S100P improves diagnostic accuracy in PDAC diagnosis, showing a better sensitivity (75%) and the same specificity compared to single markers. FISH showed an incomplete sensitivity in identifying all cases with HD of CDKN2A, with two cases MTAP negative by IHC and identified as deleted only by molecular study.

Additionally, decreased methylation of S100P_CpG_5 was markedly relevant with advanced tumor size and tumor stage (p = 0.003 and p = 0.007, respectively). Using quantitative mass spectrometry, we investigated an association between S100P hypomethylation in peripheral blood and NSCLC and suggested the great potential of DNA methylation signatures in whole blood for early detection of NSCLC.

Our findings underscore the prognostic value of the identified genes and the immunosuppressive TME in TP53-mutant breast cancer. The identification of drug candidates with strong binding affinities to key proteins provides promising avenues for targeted therapy in this high-risk patient population.

These genes were also found to be associated with tumor mutational burden (TMB) and microsatellite instability (MSI) scores. Our findings reveal how these genes contribute to CRC pathogenesis by modulating the immune microenvironment, providing important biomarkers and targets for the development of novel therapeutic strategies.

A rapid and inexpensive green synthesis process that uses deep UV LED light was used to functionalise the bimetallic substrate with S100P antibody molecules and develop an S100P-specific extractor chip. The new sensor has strong potential for the rapid determination of the S100P biomarker at points of care (POC), thus supporting the early diagnosis of cancer disease.

This study identified three LUAD subtypes with distinct immune characteristics and constructed a seven-gene prognostic model. This model correlates with immune checkpoint and chemotherapy sensitivity, providing new targets and strategies for clinical diagnosis and treatment.

Elevated expression of S100P and CTSE in PC tissues serves as independent indicators in our model of patient survival. Both proteins regulate EMT and invasion, potentially via the PI3K-AKT pathway, and hold significant promise as prognostic biomarkers and therapeutic targets in PC.

Our prognosis-related risk model based on DEGs between RCC and LCC may provide better prediction of clinical outcomes for patients with colon cancer.

These findings highlight key molecular differences in HCC across ethnicities and emphasize the value of TCGA data for identifying both shared targets and population-specific therapeutic strategies. Understanding these differences is crucial for advancing precision oncology and developing tailored interventions.